Clinical Trial Results TV
March 15, 2010: Findings from the INternational VErapamil SR – Trandolapril STudy (INVEST)
At ACC 2010, Rhonda M. Cooper-DeHoff, Pharm D, presents: Rethinking Lower Blood Pressure
Goals for Diabetic Patients with Coronary Artery Disease – Findings from the INternational
VErapamil SR – Trandolapril STudy (INVEST) .

- INVEST conduct and analysis was funded by Abbott Laboratories through 12/2008

- Cooper-DeHoff: research grant NHLBI (K23HL086558)

- Handberg: unrestricted educational grants AstraZeneca, AtCor Medical, Daiichi Sankyo,
Eli Lilly, Pfizer, Sanofi-Aventis, and Schering-Plough

- Bakris: research grants Juvenile Diabetes Research Foundation, Glaxo Smith Kline, Forest
Laboratories and CVRx; consultant Glaxo Smith Kline, Merck, Novartis,
Boehringer-Ingelheim, Takeda, Abbott Laboratories, Walgreen’s, Bristol Meyer
Squibb/Sanofi, Gilead, Forest Labs and CVRx.

- Pepine: research grants NHLBI, Baxter, Pfizer, GlaxoSmithKline, and Bioheart, Inc;
consultant Abbott Laboratories, Forest Labs, Novartis/Cleveland Clinic, NicOx, Angioblast,
Sanofi-Aventis, NIH, Medtelligence, and SLACK Inc; unrestricted educational grants
AstraZeneca, AtCor Medical, Daiichi Sankyo, Eli Lilly, Pfizer, Sanofi-Aventis, and
Schering-Plough.

- Gong, Bavry and Denardo: None


[ Download video ]


Video Statistics
4 out of 5

1 Star 2 Star 3 Star 4 Star 5 Star

click a star to vote
This submission has received 1 total votes.

These statistics are updated nightly. The last update ran on
06-19-2019 EST at 1 am.

Additional Files
Filename File Description Action
No additional files available

Comments [ login to comment ]
No comments have been submitted